Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645569 | 0.86 | RAB9A (0.34) | MBOAT4 | |
| SCHEMBL12329716 | 0.80 | MBOAT4 (0.46) | MBOAT4ITGB2ICAM1ITGALGRM5 | |
| SCHEMBL30640206 | 0.77 | NOTUM (0.43) | MBOAT4ITGB2ICAM1ITGALGRM5 | |
| SCHEMBL2799966 | 0.77 | MBOAT4 (0.43) | MBOAT4ITGB2ICAM1ITGALGRM5 | |
| SCHEMBL2437595 | 0.77 | NOTUM (0.43) | MBOAT4ITGB2ICAM1ITGALGRM5 | |
| SCHEMBL24654854 | 0.76 | GRM1 (0.33) | GRM5 | |
| SCHEMBL12299456 | 0.73 | MBOAT4 (0.37) | MBOAT4ITGB2ICAM1ITGAL | |
| SCHEMBL2431316 | 0.71 | PTGS1 (0.43) | MBOAT4GRM5 | |
| SCHEMBL2437485 | 0.71 | CYP3A4 (0.43) | MBOAT4GRM5 | |
| SCHEMBL2440894 | 0.70 | SMN1; SMN2 (0.44) | MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072683-A1 | PYRIDO-PYRIMIDIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION, FOR USE IN PREVENTING OR TREATING PI3 KINASE RELATED DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-09 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | PREP, GAA, DNPEP | MBOAT4 2253/4885ITGB2 4566/4885ICAM1 2561/4885 |
| US-20230072683-A1 | PYRIDO-PYRIMIDIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION, FOR USE IN PREVENTING OR TREATING PI3 KINASE RELATED DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | PIK3CA, PDXK, PIK3CD | MBOAT4 4700/4885ITGB2 4098/4885ICAM1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.